CoChat

Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction

Open access

The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.

Abstract

Aims: No therapy has shown to reduce the risk of hospitalization for heart failure across the entire range of ejection fractions seen in clinical practice. We assessed the influence of ejection fraction on the effect of the sodium–glucose cotransporter 2 inhibitor empagliflozin on heart failure outcomes. Methods and results: A pooled analysis was performed on both the EMPEROR-Reduced and EMPEROR-Preserved trials (9718 patients; 4860 empagliflozin and 4858 placebo), and patients were grouped based on ejection fraction: <25% (n = 999), 25–34% (n = 2230), 35–44% (n = 1272), 45–54% (n = 2260), 55–64% (n = 2092), and ≥65% (n = 865). Outcomes assessed included (i) time to first hospitalization for heart failure or cardiovascular mortality, (ii) time to first heart failure hospitalization, (iii) total (first and recurrent) hospitalizations for heart failure, and (iv) health status assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ). The risk of cardiovascular death and hospitalization for heart failure declined progressively as ejection fraction increased from <25% to ≥65%. Empagliflozin reduced the risk of cardiovascular death or heart failure hospitalization, mainly by reducing heart failure hospitalizations. Empagliflozin reduced the risk of heart failure hospitalization by ≈30% in all ejection fraction subgroups, with an attenuated effect in patients with an ejection fraction ≥65%. Hazard ratios and 95% confidence intervals were: ejection fraction <25%: 0.73 (0.55–0.96); ejection fraction 25–34%: 0.63 (0.50–0.78); ejection fraction 35–44%: 0.72 (0.52–0.98); ejection fraction 45–54%: 0.66 (0.50–0.86); ejection fraction 55–64%: 0.70 (0.53–0.92); and ejection fraction ≥65%: 1.05 (0.70–1.58). Other heart failure outcomes and measures, including KCCQ, showed a similar response pattern. Sex did not influence the responses to empagliflozin. Conclusion: The magnitude of the effect of empagliflozin on heart failure outcomes was clinically meaningful and similar in patients with ejection fractions <25% to <65%, but was attenuated in patients with an ejection fraction ≥65%. Key Question: How does ejection fraction influence the effects of empagliflozin in patients with heart failure and either a reduced or a preserved ejection fraction? Key Finding: The magnitude of the effect of empagliflozin on heart failure outcomes and health status was similar in patients with ejection fractions <25% to <65%, but it was attenuated in patients with an ejection fraction ≥65%. Take Home Message: The consistency of the response in patients with ejection fractions of <25% to <65% distinguishes the effects of empagliflozin from other drugs that have been evaluated across the full spectrum of ejection fractions in patients with heart failure.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehab798

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Figures

Structured Graphical Abstract Influence of ejection fraction on the magnitude of the effect of empagliflozin on heart failure outcomes.
Structured Graphical Abstract Influence of ejection fraction on the magnitude of the effect of empagliflozin on heart failure outcomes.CC BY-NC · PubMed Central
Figure 1 Distribution of left ventricular ejection fraction in the pooled analysis. Shown are the distributions overall, and separately, in men and women. The distribution reflects decision to limit the recruitment of patients with ejection fraction of 31–40%.
Figure 1 Distribution of left ventricular ejection fraction in the pooled analysis. Shown are the distributions overall, and separately, in men and women. The distribution reflects decision to limit the recruitment of patients with ejection fraction of 31–40%.CC BY-NC · PubMed Central
Figure 2 Cumulative incidence curves for time to cardiovascular death or heart failure hospitalization (top panel) and recurrent heart failure hospitalization (bottom panel) in the placebo group, according to ejection fraction subgroup. Shown are subgroups based on ejection fractions of <25%, 25–34%, 35–44%, 45–54%, 55–64%, and 65% or greater. There was an inverse relationship between baseline ejection fraction and the risk for serious heart failure outcomes.
Figure 2 Cumulative incidence curves for time to cardiovascular death or heart failure hospitalization (top panel) and recurrent heart failure hospitalization (bottom panel) in the placebo group, according to ejection fraction subgroup. Shown are subgroups based on ejection fractions of <25%, 25–34%, 35–44%, 45–54%, 55–64%, and 65% or greater. There was an inverse relationship between baseline ejection fraction and the risk for serious heart failure outcomes.CC BY-NC · PubMed Central
Figure 3 Effect of empagliflozin on heart failure outcomes in six ejection fraction subgroups. Shown are hazard ratios and 95% confidence intervals for four major cardiovascular outcomes in six ejection fraction subgroups. For all outcomes except for total heart failure hospitalizations, the numbers indicate patients with an event in the numerator and patients at risk in the denominator. For total (first and recurrent heart failure hospitalizations), the numbers indicate the total number of events. LVEF, left ventricular ejection fraction.
Figure 3 Effect of empagliflozin on heart failure outcomes in six ejection fraction subgroups. Shown are hazard ratios and 95% confidence intervals for four major cardiovascular outcomes in six ejection fraction subgroups. For all outcomes except for total heart failure hospitalizations, the numbers indicate patients with an event in the numerator and patients at risk in the denominator. For total (first and recurrent heart failure hospitalizations), the numbers indicate the total number of events. LVEF, left ventricular ejection fraction.CC BY-NC · PubMed Central
Figure 4 Effect of empagliflozin on heart failure hospitalizations in six ejection fraction subgroups. Shown are hazard ratios and 95% confidence intervals for the effect on time to first heart failure hospitalization (in blue) and total heart failure hospitalizations (in red).
Figure 4 Effect of empagliflozin on heart failure hospitalizations in six ejection fraction subgroups. Shown are hazard ratios and 95% confidence intervals for the effect on time to first heart failure hospitalization (in blue) and total heart failure hospitalizations (in red).CC BY-NC · PubMed Central
Figure 5 Effect of empagliflozin on time to first heart failure hospitalization in six ejection fraction subgroups, according to sex. Shown are hazard ratios and 95% confidence intervals for the effect in men (in blue) and in women (in red).
Figure 5 Effect of empagliflozin on time to first heart failure hospitalization in six ejection fraction subgroups, according to sex. Shown are hazard ratios and 95% confidence intervals for the effect in men (in blue) and in women (in red).CC BY-NC · PubMed Central
Figure 6 Influence of ejection fraction on the effect of empagliflozin on time to cardiovascular death or hospitalization for heart failure. Ejection fraction is analysed as a continuous variable, based on the assumption that the relationship is linear. Analysis of the influence of ejection fraction using cubic splines yielded a pattern similar to that observed in our six subgroups, showing a consistent risk reduction in patients with an ejection fraction <65% and an attenuated effect at the highest ejection fractions (see Supplementary material online, Figures S3–S5). Shaded areas represent 95% confidence intervals.
Figure 6 Influence of ejection fraction on the effect of empagliflozin on time to cardiovascular death or hospitalization for heart failure. Ejection fraction is analysed as a continuous variable, based on the assumption that the relationship is linear. Analysis of the influence of ejection fraction using cubic splines yielded a pattern similar to that observed in our six subgroups, showing a consistent risk reduction in patients with an ejection fraction <65% and an attenuated effect at the highest ejection fractions (see Supplementary material online, Figures S3–S5). Shaded areas represent 95% confidence intervals.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Research works printed but not linked: 1

  1. Packer, 2019, Evaluation of the effect of sodium–glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial, Eur J Heart Fail, 21, 1270, 10.1002/ejhf.1536 · DOI

Cited by

See all 264

Metadata

Authors
Butler, J., Packer, M., Filippatos, G., Ferreira, J. P., Zeller, C., Schnee, J., Brueckmann, M., Pocock, S. J., Zannad, F., & Anker, S. D.
Affiliations
  • University of Mississippi (US)
  • Baylor Jack and Jane Hamilton Heart and Vascular Hospital (US)
  • National and Kapodistrian University of Athens (GR)
  • Université de Lorraine, Inserm INI-CRCT, CHRU , Nancy, France
  • Boehringer Ingelheim (Germany) (DE)
  • Boehringer Ingelheim (United States) (US)
  • Heidelberg University (DE)
  • London School of Hygiene & Tropical Medicine (GB)
  • Inserm (FR)
  • Berlin-Brandenburger Centrum für Regenerative Therapien (DE)
Corresponding author
  • Butler, Javed
  • Packer, Milton
Venue
European Heart Journal
Published
2021-12-08
Volume
43
Issue
5
Pages
416-424
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W4200586754
Cited by
264
References
29
Citations by year
2026: 28 · 2025: 32 · 2024: 56 · 2023: 81 · 2022: 65 · 2021: 1
FWCI
33.98
Type
journal article
Language
en
Open access
Locations
  • European Heart Journal (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
  • HAL (submittedVersion, cc-by-nc)
Funders
Boehringer Ingelheim and Eli Lilly and Company
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
Keywords
empagliflozin, heart failure, left ventricular ejection fraction, SGLT2 inhibitors, heart failure hospitalization, cardiovascular mortality, EMPEROR-Reduced, EMPEROR-Preserved, Kansas City Cardiomyopathy Questionnaire, health-related quality of life, subgroup analysis, preserved ejection fraction, reduced ejection fraction, heart failure with reduced ejection fraction
MeSH terms
Benzhydryl Compounds, Glucosides, Heart Failure, Hospitalization, Humans, Stroke Volume, Ventricular Function, Left

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. https://app.cochat.ai/papers/10.1093/eurheartj/ehab798
The paper
Butler, J., Packer, M., Filippatos, G., Ferreira, J. P., Zeller, C., Schnee, J., Brueckmann, M., Pocock, S. J., Zannad, F., & Anker, S. D. (2022). Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. European Heart Journal. https://doi.org/10.1093/eurheartj/ehab798

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.